Neuphoria Therapeutics Inc. (NEUP) Research

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

Market snapshot

Symbol
NEUP
Price
$4.31
Day change
0.00%
Market cap
$23.3M
P/E ratio
-0.85x
52-week range
3.645-21.4
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Next earnings
in 2 months
Analyst price target
$7.00

Peer companies

  • Alzamend Neuro, Inc. (ALZN)
  • Aprea Therapeutics, Inc. (APRE)
  • BioCardia, Inc. (BCDA)
  • Biomerica, Inc. (BMRA)
  • Check-Cap Ltd. (CHEK)
  • Inspira Technologies Oxy B.H.N. Ltd. (IINN)
  • Lifeward Ltd. (LFWD)
  • Innovative Eyewear, Inc. (LUCY)

Recent insider activity

  • Wilson David Ian — A-Award (8537 shares) on 2026-01-20
  • Davies Peter Miles Winston — A-Award (8537 shares) on 2026-01-20
  • Fisher Alan — A-Award (17073 shares) on 2026-01-20
  • Ryan Jane — A-Award (8537 shares) on 2026-01-20
  • Lynx1 Capital Management LP — P-Purchase (639110 shares) on 2025-10-21

Open Neuphoria Therapeutics Inc. (NEUP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.